Alterations in GILZ/c-Rel/RACK1 Signaling Compromise Epithelial Barrier in IBD

Overview

This study identifies a significant decrease in RACK1 expression in inflammatory bowel disease (IBD), particularly ulcerative colitis, linked to impaired epithelial barrier function. The findings reveal that reduced GILZ protein correlates with diminished RACK1, leading to SRC activation and E-cadherin reduction, disrupting intestinal epithelial integrity. Notably, dexamethasone restores RACK1 expression independently of c-Rel/GILZ, suggesting new therapeutic avenues.

Background

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is characterized by chronic gastrointestinal inflammation and impaired epithelial barrier function. The intestinal barrier relies on tight junctions and adherent junctions, which are compromised by inflammatory cytokines such as TNF-α, IL-1β, and IFNγ. Glucocorticoids remain a first-line treatment despite side effects and variable efficacy. RACK1, a scaffold protein involved in immune activation and epithelial integrity, is transcriptionally regulated by glucocorticoids and may play a critical role in IBD pathogenesis.

Data Highlights

Key Findings

• RACK1 expression is significantly reduced in intestinal mucosa of IBD patients and mouse colitis models.
• GILZ protein levels positively correlate with RACK1 expression, implicating GILZ in RACK1 regulation.
• GILZ knockout and silencing experiments confirm that GILZ depletion lowers RACK1, activates SRC kinase, and decreases E-cadherin, impairing epithelial barrier integrity.
• The NF-κB/c-Rel pathway is involved in the regulation of RACK1 expression in IBD.
• Dexamethasone restores RACK1 expression through the glucocorticoid receptor independently of c-Rel and GILZ, suggesting alternative regulatory mechanisms.
• Alterations in the RACK1/SRC/E-cadherin axis contribute to epithelial barrier disruption in IBD.

Clinical Implications

These findings highlight the importance of the GILZ/c-Rel/RACK1 signaling axis in maintaining intestinal epithelial barrier integrity in IBD. Therapeutic strategies aimed at restoring RACK1 expression or modulating SRC activation may improve barrier function and disease outcomes. Additionally, dexamethasone’s ability to restore RACK1 independently of GILZ/c-Rel suggests potential benefits in patients with glucocorticoid resistance.

Conclusion

The study provides novel evidence that disruption of GILZ/c-Rel-mediated RACK1 expression compromises epithelial barrier function in IBD. Targeting this pathway may enhance therapeutic efficacy, particularly for patients with poor glucocorticoid response.

References

1. Original Article 2024 -- Alterations in GILZ/c-Rel/RACK1 Signaling Compromise Epithelial Barrier Function in Inflammatory Bowel Disease